心脉医疗(688016) - 2023 Q1 - 季度财报

Financial Performance - In Q1 2023, the company reported a revenue of ¥285,591,399.25, representing a year-on-year increase of 10.75%[13] - The net profit attributable to shareholders was ¥124,840,722.70, showing a slight increase of 1.10% compared to the same period last year[13] - Total revenue for Q1 2023 was CNY 285,591,399.25, an increase of 10.3% compared to CNY 257,879,693.03 in Q1 2022[48] - Net profit for Q1 2023 was CNY 123,553,343.99, slightly up from CNY 122,074,575.79 in Q1 2022, reflecting a growth of 1.2%[50] - Basic earnings per share for Q1 2023 was CNY 1.73, compared to CNY 1.72 in Q1 2022[51] Research and Development - R&D expenses totaled ¥60,844,478.10, up 43.51% year-on-year, accounting for 21.30% of the operating revenue, an increase of 4.86 percentage points[15] - The company plans to submit registration materials for 13 new products and has 7 products entering clinical trial phases within the year[15] - Research and development expenses for Q1 2023 were CNY 36,218,269.91, up from CNY 34,289,792.96 in Q1 2022, indicating a 5.6% increase[48] Market Expansion - The company expanded its overseas market presence to 25 countries, with overseas sales revenue increasing by 138% year-on-year[6] - The number of Castor branched aortic stent grafts implanted increased by 24.32% year-on-year, while Minos abdominal aortic stent grafts saw a 45.51% increase, and Reewarm PTX drug-coated balloon catheters grew by 62.54%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,159,243,634.08, an increase of 8.23% from the end of the previous year[5] - Total current assets reached RMB 1,418,277,564.28, an increase from RMB 1,294,342,713.72 at the end of 2022[36] - The company's cash and cash equivalents stood at RMB 1,070,704,082.25, up from RMB 976,893,164.69 at the end of 2022[33] - Total liabilities increased to RMB 288,423,366.04 from RMB 252,494,169.40 at the end of 2022[39] - The total equity attributable to shareholders was RMB 1,847,907,675.33, up from RMB 1,718,668,312.38 at the end of 2022[39] Cash Flow - The net cash flow from operating activities was ¥119,389,672.63, reflecting a decrease of 17.85% compared to the same period last year[13] - Cash flow from operating activities in Q1 2023 was CNY 325,268,253.52, an increase from CNY 293,795,410.32 in Q1 2022[52] - Net cash flow from operating activities was $119,389,672.63, a decrease of 17.8% compared to $145,322,872.72 in the previous period[54] - Total cash outflow from operating activities amounted to $205,878,580.89, up from $148,472,537.60, indicating a significant increase in operational expenses[54] Expenses - Total operating costs for Q1 2023 were CNY 145,144,980.49, up from CNY 122,556,913.84 in Q1 2022, representing a 18.4% increase[48] - Sales expenses for Q1 2023 were CNY 25,073,250.27, compared to CNY 20,123,974.33 in Q1 2022, marking a 24.6% increase[48] - Cash paid to employees was $67,772,259.07, compared to $51,107,792.74 previously, reflecting a 32.5% increase[54] - Cash paid for taxes was $32,682,998.65, down from $37,018,037.93, indicating a 11.0% decrease[54] Other Financial Metrics - The weighted average return on equity decreased to 7.00%, down 0.92 percentage points from the previous year[5] - The company reported a net loss of RMB 4,701.90 from non-current asset disposal due to unauthorized approvals or lack of formal documentation[26] - Government subsidies recognized in the current period amounted to RMB 2,622,312.75, closely related to the company's normal business operations[26] - The company did not execute any mergers or acquisitions during this reporting period, with net profit from merged entities remaining at CNY 0[43]